Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 King Pharma to Acquire Alpharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

King Pharma to Acquire Alpharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

King Pharmaceuticals, Inc. has agreed to acquire Alpharma, Inc. for approximately $1.6 billion. The agreement, if approved by shareholders, will expand King’s pain drug business with Alpharma’s drug Kadian and pain patch Flector. Alpharma also has an experimental pain drug Embeda.
   
An FDA advisory panel recently stated that the morphine-based Embeda is somewhat less attractive to drug abusers, which the agency may require the company to claim on its label. King and partner Pain Therapeutics have a similar drug, Remoxy, pending approval. An advisory panel said Remoxy appeared less susceptible to abuse than other similar drugs such as Purdue Pharma’s Oxycontin.
   
According to a company statement, King expects to achieve cost savings of $50 million to $70 million in the second full year following completion of the transaction, mainly from general and administrative cost cuts and R&D savings, as well as avoiding the expense of new sales representatives for the launch of its new pain drug.
   
In 2007 King’s revenue was $2.7 billion and Alpharma’s revenue was $722 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters